Exchange Traded Concepts LLC Has $14.23 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Exchange Traded Concepts LLC raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319,682 shares of the company’s stock after buying an additional 20,031 shares during the period. Exchange Traded Concepts LLC owned 0.69% of Omnicell worth $14,232,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OMCL. GAMMA Investing LLC grew its holdings in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the last quarter. 1620 Investment Advisors Inc. raised its stake in Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares during the period. Summit Global Investments acquired a new stake in Omnicell in the 3rd quarter valued at $221,000. QRG Capital Management Inc. bought a new stake in shares of Omnicell during the third quarter worth about $231,000. Finally, Everence Capital Management Inc. bought a new stake in Omnicell during the third quarter worth $249,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Trading Up 0.1 %

NASDAQ:OMCL opened at $43.21 on Friday. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74. The business’s 50-day moving average is $44.71 and its 200 day moving average is $42.01. The company has a market capitalization of $2.00 billion, a P/E ratio of -110.36, a P/E/G ratio of 29.73 and a beta of 0.78.

Insider Buying and Selling

In related news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.64% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company cut their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. Bank of America cut their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Barclays lifted their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Craig Hallum increased their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $50.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.